203 related articles for article (PubMed ID: 34230199)
1. Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research.
Wallis D; Stemmer-Rachamimov A; Adsit S; Korf B; Pichard D; Blakeley J; Sarin KY;
Neurology; 2021 Aug; 97(7 Suppl 1):S42-S49. PubMed ID: 34230199
[TBL] [Abstract][Full Text] [Related]
2. Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
Hanemann CO; Blakeley JO; Nunes FP; Robertson K; Stemmer-Rachamimov A; Mautner V; Kurtz A; Ferguson M; Widemann BC; Evans DG; Ferner R; Carroll SL; Korf B; Wolkenstein P; Knight P; Plotkin SR;
Neurology; 2016 Aug; 87(7 Suppl 1):S40-8. PubMed ID: 27527649
[TBL] [Abstract][Full Text] [Related]
3. Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
Cannon A; Pichard DC; Wolters PL; Adsit S; Erickson G; Lessing AJ; Li P; Narmore W; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S15-S24. PubMed ID: 34230202
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.
Sundby RT; Rhodes SD; Komlodi-Pasztor E; Sarnoff H; Grasso V; Upadhyaya M; Kim A; Evans DG; Blakeley JO; Hanemann CO; Bettegowda C
Clin Trials; 2024 Feb; 21(1):40-50. PubMed ID: 37904489
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.
Merker VL; Thompson HL; Wolters PL; Buono FD; Hingtgen CM; Rosser T; Barton B; Barnett C; Smith T; Haberkamp D; McManus ML; Baldwin A; Moss IP; Röhl C; Martin S
Clin Trials; 2024 Feb; 21(1):6-17. PubMed ID: 38140900
[TBL] [Abstract][Full Text] [Related]
6. The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities.
Brosseau JP; Pichard DC; Legius EH; Wolkenstein P; Lavker RM; Blakeley JO; Riccardi VM; Verma SK; Brownell I; Le LQ
Neurology; 2018 Jul; 91(2 Suppl 1):S14-S20. PubMed ID: 29987131
[TBL] [Abstract][Full Text] [Related]
7. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO;
Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous neurofibromas in the genomics era: current understanding and open questions.
Allaway RJ; Gosline SJC; La Rosa S; Knight P; Bakker A; Guinney J; Le LQ
Br J Cancer; 2018 Jun; 118(12):1539-1548. PubMed ID: 29695767
[TBL] [Abstract][Full Text] [Related]
9. Considerations for development of therapies for cutaneous neurofibroma.
Verma SK; Riccardi VM; Plotkin SR; Weinberg H; Anderson RR; Blakeley JO; Jarnagin K; Lee J
Neurology; 2018 Jul; 91(2 Suppl 1):S21-S30. PubMed ID: 29987132
[TBL] [Abstract][Full Text] [Related]
10. [Segmental schwannomatosis in upper-extremity: 5 cases report and literature review].
Wang ZX; Chen SL; Yi CJ; Li C; Rong YB; Tian GL
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Oct; 45(5):698-703. PubMed ID: 24136261
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience.
Peltonen S; Jannic A; Wolkenstein P
Eur J Med Genet; 2022 Jan; 65(1):104386. PubMed ID: 34768015
[TBL] [Abstract][Full Text] [Related]
12. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
[TBL] [Abstract][Full Text] [Related]
13. Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.
Merker VL; Gross AM; Widemann BC; Plotkin SR
Clin Trials; 2024 Feb; 21(1):3-5. PubMed ID: 37776044
[No Abstract] [Full Text] [Related]
14. Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients.
Harder A; Wesemann M; Hagel C; Schittenhelm J; Fischer S; Tatagiba M; Nagel C; Jeibmann A; Bohring A; Mautner VF; Paulus W
Am J Surg Pathol; 2012 May; 36(5):702-9. PubMed ID: 22446939
[TBL] [Abstract][Full Text] [Related]
15. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.
Nguyen HTL; Kohl E; Bade J; Eng SE; Tosevska A; Al Shihabi A; Tebon PJ; Hong JJ; Dry S; Boutros PC; Panossian A; Gosline SJC; Soragni A
Cell Rep Methods; 2024 May; 4(5):100772. PubMed ID: 38744290
[TBL] [Abstract][Full Text] [Related]
16. Superficial neurofibromas in the setting of schwannomatosis: nosologic implications.
Rodriguez FJ; Scheithauer BW; George D; Midha R; MacCollin M; Stemmer-Rachamimov AO
Acta Neuropathol; 2011 May; 121(5):663-8. PubMed ID: 21191601
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial design for cutaneous neurofibromas.
Cannon A; Jarnagin K; Korf B; Widemann BC; Casey D; Ko HS; Blakeley JO; Verma SK; Pichard DC
Neurology; 2018 Jul; 91(2 Suppl 1):S31-S37. PubMed ID: 29987133
[TBL] [Abstract][Full Text] [Related]
18. Hemidiaphragmatic palsy following excision of cervical dumbbell neurofibroma in a patient with neurofibromatosis: Importance of assessing functional status of "non-limb" roots.
Krishnan P; Kartikueyan R; Kumar SK
Br J Neurosurg; 2016; 30(1):97-8. PubMed ID: 26140388
[TBL] [Abstract][Full Text] [Related]
19. A rare occurrence and management of familial schwannomatosis.
Reddy RG; Banda VR; Gunadal S; Banda NR
BMJ Case Rep; 2013 Apr; 2013():. PubMed ID: 23595180
[TBL] [Abstract][Full Text] [Related]
20. Six cases of sporadic schwannomatosis: Topographic distribution and outcomes of peripheral nerve tumors.
Chick G; Victor J; Hollevoet N
Hand Surg Rehabil; 2017 Oct; 36(5):378-383. PubMed ID: 28781128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
